Skip to main content


Fig. 5 | Cell Communication and Signaling

Fig. 5

From: Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer

Fig. 5

IL-32θ inhibits tumor formation in a breast cancer xenograft model. a Schematic of mouse model 1: MDA-MB-231-EV and/or MDA-MB-231-IL-32θ cells were injected into the flanks of mice (n = 10/ group). Tumors from two mouse groups were extracted after 35 days and analyzed. b Images are presented from hematoxylin-eosin (HE) staining and immunohistochemistry staining of section from tumors. Immunohistochemistry images are the representative of ten sections. c Tumor size was measured after 35 days. d mRNA expression levels of pro-malignancy factors were quantitated by real-time PCR. e Schematic of mouse model 2: MDA-MB-231-EV and/or MDA-MB-231-IL-32θ cells were treated with THP-1 CM for 24 h then probe administrated for 24 h before intravenous injection into mice (n = 5/ group). f After 35 days, tumor localization was analyzed by IRDye®-2DG infrared optical probe-guided analysis. Representative imaging data of breast cancer cell-induced solid tumors in mice. g Fluorescence intensities were obtained by ImageJ software. Scale bar, 100 μm. Data are presented as the mean ± SEM and are analyzed using the Student’s t-test: *, p < 0.05

Back to article page